Market Overview

UPDATE: Piper Jaffray Upgrades BioDelivery Sciences International to Overweight on Checks

Related BDSI
BioDelivery Sciences Appoints Charles J. Bramlage And Dr. Barry I. Feinberg To Its Board Of Directors
Companhia Paranaense Leads Energy Sector; Peabody Drops Over 14%

Piper Jaffray upgraded BioDelivery Sciences International (NASDAQ: BDSI) from Neutral to Overweight and raised the price target from $5.00 to $8.00.

Piper Jaffray noted, "We continue to view BBCP as a valueadded offering for pain and expect the Phase III studies to prove positive based on revised trial designs. Most encouraging, in our view, was bioequivalence data for Bunavail, suggesting possible superiority to Suboxone. As a result of this and other diligence, we are adjusting our model to reflect the recently approved Suboxone generic but also a potential BNX advantage based on these data. Bunavail's NDA filing is planned for July and both BBCP Phase IIIs readout by YE13 or early 2014."

BioDelivery Sciences International closed at $4.05 on Friday.

Posted-In: Piper JaffrayAnalyst Color Upgrades Analyst Ratings

 

Most Popular

Related Articles (BDSI)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters